PUNE, India, July 21, 2017 /PRNewswire/ --
Erectile Dysfunction Pipeline Drugs and Therapeutics Market H2
2017 report provides latest therapeutics and drugs development for
Erectile Dysfunction by major key players with their dormant and
discontinued project. Complete report on Erectile Dysfunction -
Pipeline Review, H2 2017 spread across 112 pages is available
at http://www.rnrmarketresearch.com/erectile-dysfunction-pipeline-review-h2-2017-market-report.html.
Erectile Dysfunction Pipeline Review H2 2017 provides
comprehensive information on the therapeutics under development for
Erectile Dysfunction Drugs (Male Health) complete with analysis by
stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press
releases.
Erectile dysfunction, or ED, is the inability of a man to have
an erection hard enough to have sexual intercourse. It can also be
known as impotence. The predisposing factors include tobacco usage,
overweight, injuries, drug and alcohol use and medications,
including antidepressants, antihistamines and medications to treat
high blood pressure, pain or prostate cancer. Order a copy of
this research report at
http://www.rnrmarketresearch.com/contacts/purchase?rname=1141789.
The Erectile Dysfunction (Male Health) pipeline guide also
reviews of key players involved in therapeutic development for
Erectile Dysfunction and features dormant and discontinued
projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by
Companies in Pre-Registration, Filing rejected/Withdrawn, Phase
III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and
Unknown stages are 2, 2, 4, 5, 3, 2, 13, 3 and 2 respectively.
Similarly, the Universities portfolio in Phase I and Preclinical
stages comprises 1 and 1 molecules, respectively.
Companies discussed in this report include Apricus
Biosciences Inc , Astellas Pharma Inc , Biolab Farmaceutica Ltda ,
Biopharm GmbH , Can-Fite BioPharma Ltd , Fabre-Kramer
Pharmaceuticals Inc , Futura Medical Plc , Hanmi Pharmaceuticals Co
Ltd , Humanetics Corp , IntelGenx Corp , Ion Channel Innovations
LLC , iX Biopharma Ltd , Mezzion Pharma Co Ltd, Mitsubishi Tanabe
Pharma Corp , Monosol Rx LLC , N4 Pharma Plc , NAL Pharmaceuticals
Ltd , Nanoform Cardiovascular Therapeutics Ltd , Palatin
Technologies Inc , Pharmicell Co Ltd , SK Chemicals Co Ltd , Suda
Ltd , XuanZhu Pharma Co Ltd , Yangtze River Pharmaceutical Group ,
Yungjin Pharm Co Ltd.
Drug Profile Discussed In Report: alprostadil , AP-185 ,
avanafil , BIO-300 , BL-214 , Cellgram-ED , CF-602 , fadanafil ,
FKK-01PD , HCP-1302 , IPED-2015 , MED-2002 , MED-2005 , mirabegron
ER , moxisylyte , Peptide to Activate G Protein-Coupled Receptor
Mas for Cardiovascular, Metabolic Disorders and Male Health ,
pVAX-hSlo , Recombinant Protein for Bone Fracture, Degenerative
Disc Disease, Erectile Dysfunction and Parkinson's Disease ,
sildenafil , sildenafil citrate , sildenafil citrate , sildenafil
citrate , sildenafil citrate , Small Molecule to Inhibit PDE5 for
Erectile Dysfunction , SUD-003 , Synthetic Peptide to Agonize
Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile
Dysfunction , T-6932 , tadalafil , tadalafil , tadalafil ,
tadalafil , tadalafil , TF-0092 , TPN-729 , TR-399 , udenafil ,
YBH-1603 , Yonkenafil.
Related reports on Erectile Dysfunction:
Erectile Dysfunction - Epidemiology Insights to 2025
Erectile Dysfunction - Epidemiology Forecast To 2025" provides
an overview of the epidemiology trends of Erectile Dysfunction in
seven major markets (US, France,
Germany, Italy, Spain,
UK and Japan). It includes 10
years epidemiology historical and forecasted data of Erectile
Dysfunction prevalent or incident cases segmented by age, sex and
subpopulations. The Report also discusses the prevailing risk
factors, disease burden with special emphasis on the unmet medical
need associated with the Erectile Dysfunction. The report is built
using data and information sourced from proprietary databases,
primary and secondary research and in-house Forecast model analysis
by team of industry experts.
Explore more reports of Therapeutics Market Research
at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.
About Us:
RnRMarketResearch.com is your one stop market research and
industry analysis reports' library providing business data and
intelligence information on thousands of micro markets with global
as well as regional coverage. Category focused research, country
reports, company profiles, regional and global industry profiles
and guides to premium reports offering extensive coverage of other
20+ industries are all available in our library of syndicated
market research reports.
Contact:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: +1-888-391-5441
E-mail: sales@rnrmarketresearch.com
SOURCE RnRMarketResearch